Bayer Logo
Bayer Logo


Clear Direction. Experience gives U confidence.

Ultravist® is an iodine-containing X-ray contrast agent, approved for X-ray techniques

  • Launched in 1985
  • Over 250 million applications to patients (Ref A)
  • Available in +100 countries (Ref A)
  • Currently being applied more than 16 million times a year (Ref A)
  • Over 150.000 patients in observational studies (Ref B, C

What is Ultravist®?

Ultravist® is an Iodine based non-ionic monomeric low osmolar extracellular X-ray contrast medium (LOCM). It can be used for X-ray techniques requiring contrast enhancement such as conventional radiography, angiography and computed tomography (see Product Information).

Indications and Clinical Use

Ultravist® (iopromide), provided as 300 mg I/mL and 370 mg I/mL, is indicated for:

  • Intravascular use to provide diagnostic information in a number of radiographic contrast procedures.
  • Visualization of various body cavities, eg, arthrography and hysterosalpingography.


Ultravist® 300

Computed tomography (CT)

Excretory urography

Pediatric excretory urography

Renal arteriography

Peripheral arteriography (bifemoral pelvis/leg)

Cerebral arteriography

Phlebography of the extremities


Ultravist® 370

Computed tomography (CT)

Excretory urography

Coronary arteriography (including PTCA), with or without left ventriculography

Pediatric angiocardiography



* Please read the Product Monograph for approved indications


    Name of the medicinal product: Ultravist® 300/370 solution for injection / infusion

    Composition: Ultravist® 300, 370: 1 mL contains 0.623 g/ 0.769 g iopromide (equivalent to 300 mg / 370 mg iodine).

    Each mL contains 0.000534 mmol (equivalent to 0.0123 mg) of sodium.

    Indications: This medicinal product is for diagnostic use only.

    Ultravist® 300/370: For intravascular use and use in body cavities. Contrast enhancement in computerized tomography (CT), arteriography and venography, intravenous/intraarterial digital subtraction angiography (DSA); intravenous urography, use for ERCP, arthrography and examination of other body cavities.

    Ultravist® 370: Especially for angiocardiography.


    • Ultravist® is contraindicated for use in myelography, cerebral ventriculography, and cisternography.
    • Ultravist® is contraindicated in patients with manifest hyperthyroidism.
    • Ultravist® should not be administered to patients with known hypersensitivity to the drug or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING).
    • Ultravist® 300 and Ultravist® 370 are contraindicated for intrathecal use.
    • Preparatory dehydration, including prolonged fasting, restriction of fluids and the administration of a laxative before Ultravist® Injection, is contraindicated in pediatric patients because of the risk of renal failure (see 7.1.3 Pediatrics).


    Nonionic iodinated contrast media (ICM) inhibit blood coagulation less than ionic contrast media. Clotting has been reported in vivo and in vitro when blood remains in contact with syringes, catheters or tubes containing nonionic contrast media. Nonionic contrast media are not suitable flush solutions.

    Ultravist® has been associated with serious and fatal reactions. Therefore, clear indication and evaluation of the benefit/risk ratio for every patient should precede each examination with contrast media. Also, it is of utmost importance that adequate facilities and appropriate personnel be readily available and a course of action be planned in advance for the immediate treatment of any serious untoward reaction. Diagnostic procedures utilizing a radiopaque contrast agent should be conducted only by a physician with the requisite training and a thorough knowledge of the particular procedure to be performed. The physician must also be thoroughly familiar with the emergency treatment of all adverse effects.

    As with other iodinated contrast agents, the use of Ultravist® contrast enhancement may obscure some lesions which were seen on previously unenhanced CT scans.

    Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. Careful optimization of contrast and radiation parameters can decrease radiation exposure.

    Caution is advised in patients with cardiac and circulatory insufficiency, hypertension, pheochromocytoma, cerebral arteriosclerosis, latent hyperthyroidism, severe impairment of hepatic or renal function, pulmonary emphysema, diabetes with renal dysfunction requiring treatment, cerebral arterial spasm, bland nodular goiter, multiple myeloma or other paraproteinemias, and renal transplant.

    Avoid angiography whenever possible in patients with homocystinuria because of the risk of inducing thrombosis and embolism.

    Pronounced states of excitement, anxiety and pain may increase the risk of side effects or intensify contrast medium-related reactions. Care should be taken to minimize the state of anxiety in such patients.

    Sensitivity testing using a small test dose of contrast medium is not recommended as it has no predictive value. Furthermore, sensitivity testing itself has occasionally led to serious and even fatal hypersensitivity/anaphylactoid reactions.

    Dosage and Administration

    • Solutions of Ultravist®, like those of other radiopaque contrast agents, should be at or close to body temperature when injected. As with other sterile parenteral products, Ultravist® should not be withdrawn from the vial except immediately prior to use (see 7 WARNINGS AND PRECAUTIONS, General). Ultravist® should not be mixed with other medicinal products to avoid the risk of possible incompatibilities. Any unused portion should be discarded.
    • For additional instructions see 11 STORAGE, STABILITY AND DISPOSAL.
    • Vials containing contrast medium solutions are not intended for the withdrawal of multiple doses, with the exception of Ultravist® Pharmacy Bulk Vials (see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING, and 4.4 Administration, DIRECTIONS FOR MULTIPLE DISPENSING FROM PHARMACY BULK VIALS). The rubber stopper should never be pierced more than once. The use of a cannula or needle with a long tip and a maximum diameter of 18 G is recommended for piercing the stopper and drawing up the contrast medium. With the exception of Ultravist® Pharmacy Bulk Vials (see 4.4 Administration, DIRECTIONS FOR MULTIPLE DISPENSING FROM PHARMACY BULK VIALS), any contrast solution not used in one examination for a given patient is to be discarded.
    • In the case of abdominal angiography and urography, the diagnostic yield is increased if the bowels are empty of fecal matter and gas. It may be necessary to administer an enema or laxative in the evening prior to examination, provided purging of the bowels is not contraindicated.
    • In infants and young children, prolonged fasting, restriction of fluids and the administration of a laxative before the examination are contraindicated. See 7.1.3 Pediatrics.
    • Intravascular administration of contrast media should, if possible, be done with the patient lying down. After the administration, the patient should be kept under observation for at least 30 minutes, since experience shows that the majority of all severe incidents occur within this time.
    • The recommended dosages of Ultravist® should not be exceeded. The volume of each individual injection is a more important consideration than the total dose used.
    • Determine the volume and concentration of Ultravist® to be used, taking into account factors such as age, body weight, size of the vessel and the rate of blood flow within the vessel; consider also extent of opacification required, structure(s) or area to be examined, disease processes affecting the patient, and equipment and technique to be employed. As with all iodinated contrast agents, lower doses may have less risk. The efficacy of Ultravist® below doses recommended has not been established.

    Please visit the Product Monograph for additional product information.

    If you want to report a side effect or quality complaint, please contact your healthcare professional (e.g. physician or pharmacist) or your local health authority.

    Side effects can also be reported to Bayer Inc. by clicking here.

    Key Studies

    Since the market introduction in 1985 (FDA approval 1995) the safety profile of Ultravist® has been investigated in a number of large-scale studies (clinical, observational, preclinical).


    Clinical Safety Overview

    Summary of a total of 1367 patients from controlled clinical trials (Iopromide 708, comparators 659) – Berlex Laboratories, NDA 20-220 to FDA, USA (1994)

    Palkowitsch PK et al. Acta Radiol 2014;55(6):707–14.

    Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients.

    This pooled analysis confirms the well-established good safety profile of iopromide in clinical practice in Asian and European countries and the US


    Mortelé KJ et al. AJR 2005;184(1):31-4.

    Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital.

    This 2 year study followed 29,508 consecutive patients. Results showed low rates of adverse reactions, the most common being urticaria (0.55%) and nausea and vomiting (0.03%). Contrast quality was rated as either ‘good’ or ‘excellent’ for the vast majority of patients (94.8%).


    Krause W et al. Eur J Clin Pharmacol 1994;46(4):339–43.

    Dose proportionality of iopromide pharmakokinetics and tolerability after IV injection in healthy volunteers.

    Iopromide is almost completely excreted via glomerular filtration. Only a negligible amount of the compound is eliminated with the feces. The total clearance of iopromide equals its renal clearance.



    Ref A Bayer data reported to Health Authorities (Status July 2018), PERIODIC BENEFIT-RISK EVALUATION REPORT/PERIODIC SAFETY UPDATE REPORT (PBRER/PSUR) Ultravist® 150/240/300/370 BAY No. 86-4877 (Iopromide)

    No 241. 28 AUG 2018, Bayer AG

    Ref B Palkowitsch, Bostelmann, Lengsfeld. Safety and tolerability of Iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients Acta Radiologica, 55(6) 707–714 (2014)

    Ref C Chen et al. Safety and tolerability of iopromide in patients undergoing cardiac catheterization: real-world multicenter experience with 17,513 patients from the TRUST trial Int J Cardiovasc Imaging 31:1281–1291 (2015)